EW vs MDT
Edwards Lifesciences and Medtronic, both Healthcare
Medtronic is the larger company at $102B against $50B. On trailing earnings MDT is the cheaper of the two at a P/E of 21.7 against 49.0, a gap that is only a bargain if the two are growing at similar rates. Over the past year EW returned +14% against -5.3% for MDT. The RyuScore puts MDT ahead, 62 against 60 out of 100.
| Figure | EW | MDT |
|---|---|---|
| Last close | $85.20 | $88.48 |
| Market cap | $50B | $102B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 49.0 | 21.7 |
| Dividend yield | n/a | 3.2% |
| 1-year return | +14% | -5.3% |
| 5-year return | -29% | -21% |
| RyuScoresector-relative, 1–10 | 60/100 | 62/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Edwards Lifesciences
Revenue of $1.7B in Q2 2026, net income $241M. Its largest reported line is Transcatheter Aortic Valve Replacement, 72% of the disclosed total.
Medtronic
Revenue of $9.8B in Q1 2027, net income $1.5B. Its largest reported line is Total Other Countries Excluding Ireland, 100% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.